Kelly Shanahan, Director at METAvivor Research And Support, shared Bishal Gyawali’s, Professor at Queen’s University, post on X, adding:
“So much this! Bishal Gyawali expresses what we patients have been saying for years – don’t trivialize AEs, don’t use adjectives like ‘tolerable’ unless you’ve taken the drug, just give us the facts.”
Quoting Bishal Gyawali’s post:
“The most important paper of ASCO26 just dropped in Nature Med! Or any other ASCO or ESMO meetings to be honest. When you hear someone present ‘the toxicities were acceptable’, please respond ‘downplaying toxicities is not acceptable’. Thank you Nature Medicine for publishing this piece.
Great to see that there is also a simultaneous paper published from the patient’s perspective. A must read!”
Title: Downplaying toxicities in cancer drug trials is not acceptable
Author: Bishal Gyawali
Other articles featuring Kelly Shanahan and Bishal Gyawali on OncoDaily.